Brokerages Set Bioventus Inc. (NASDAQ:BVS) PT at $14.20

Shares of Bioventus Inc. (NASDAQ:BVS) have been given an average recommendation of “Buy” by the six analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $14.20.

A number of analysts have commented on the stock. Craig Hallum upped their target price on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. Barrington Research reaffirmed an “outperform” rating and set a $14.00 target price on shares of Bioventus in a report on Friday, May 22nd. Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 target price on shares of Bioventus in a report on Tuesday, June 16th. CJS Securities initiated coverage on shares of Bioventus in a report on Friday, March 27th. They set a “market outperform” rating and a $14.00 target price for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a report on Tuesday, June 2nd.

Institutional Trading of Bioventus

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its holdings in Bioventus by 17,156.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after acquiring an additional 5,490 shares during the period. Prelude Capital Management LLC purchased a new stake in shares of Bioventus during the third quarter worth about $74,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Bioventus during the third quarter worth about $78,000. SG Americas Securities LLC purchased a new stake in shares of Bioventus during the fourth quarter worth about $80,000. Finally, Brooklyn Investment Group purchased a new stake in shares of Bioventus during the fourth quarter worth about $91,000. 62.94% of the stock is owned by hedge funds and other institutional investors.

Bioventus Price Performance

Shares of BVS opened at $9.50 on Friday. The firm has a market cap of $793.63 million, a PE ratio of 23.17, a P/E/G ratio of 1.20 and a beta of 0.67. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08. The firm has a fifty day simple moving average of $9.56 and a two-hundred day simple moving average of $8.71. Bioventus has a 1-year low of $5.81 and a 1-year high of $11.25.

Bioventus (NASDAQ:BVS) last announced its earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. The business had revenue of $132.09 million during the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities analysts anticipate that Bioventus will post 0.77 EPS for the current year.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.